Alzamend Neuro, Inc.

Contributing Author

Recent Articles by Alzamend Neuro, Inc.

Jul-28	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium ALZN -6.42% GlobeNewswire
Jul-23	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs ALZN -5.94% GlobeNewswire
Jun-16	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule ALZN GlobeNewswire
May-29	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital ALZN +63.86% GlobeNewswire
May-19	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital ALZN +5.88% GlobeNewswire
May-13	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital ALZN -18.83% GlobeNewswire
May-08	Alzamend Neuro Announces Reverse Stock Split ALZN -9.40% GlobeNewswire
May-07	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital ALZN -6.22% GlobeNewswire